NEW YORK, Nov. 16 - Celera Genomics’ acquisition of Axys Pharmaceuticals was formally approved by the US Securities and Exchange on Friday, Celera said. The transaction will be put to bed at the close of business in California on Friday and from then on Axys will do business under the Celera name.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.